The application and biology of immunomodulatory drugs (IMiDs) in cancer

Ades, 2009, Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. [Clinical Trial, Phase II], Blood, 113, 3947, 10.1182/blood-2008-08-175778 Andritsos, 2008, Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia, J Clin Oncol, 26, 2519, 10.1200/JCO.2007.13.9709 Attal, 2006, Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, 108, 3289, 10.1182/blood-2006-05-022962 Attal, 2012, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma, N Engl J Med, 366, 1782, 10.1056/NEJMoa1114138 Aue, 2011, Inflammation, TNFalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia, Am J Hematol, 86, 835, 10.1002/ajh.22114 Badoux, 2011, Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia, Blood, 118, 3489, 10.1182/blood-2011-03-339077 Barlogie, 2010, Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences, J Clin Oncol, 28, 1209, 10.1200/JCO.2009.25.6081 Barlogie, 2008, Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities, Blood, 112, 3115, 10.1182/blood-2008-03-145235 Barlogie, 2006, Thalidomide and hematopoietic-cell transplantation for multiple myeloma, N Engl J Med, 354, 1021, 10.1056/NEJMoa053583 Begna, 2011, A phase-2 trial of low-dose pomalidomide in myelofibrosis, Leukemia, 25, 301, 10.1038/leu.2010.254 Beksac, 2011, Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, Eur J Haematol, 86, 16, 10.1111/j.1600-0609.2010.01524.x Bergsagel, 1979, The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia, N Engl J Med, 301, 743, 10.1056/NEJM197910043011402 Bibas, 2010, Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone, J Clin Oncol, 28, e704, 10.1200/JCO.2010.30.0038 Blum, 2010, Dose escalation of lenalidomide in relapsed or refractory acute leukemias. [Clinical Trial, Phase I Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't], J Clin Oncol, 28, 4919, 10.1200/JCO.2010.30.3339 Breitkreutz, 2007, Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield, Leukemia, 21, 1294, 10.1038/sj.leu.2404661 Caravita, 2011, Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience, Ann Hematol, 90, 115, 10.1007/s00277-010-0967-4 Cavallo, 2011, Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy, Leukemia, 25, 1627, 10.1038/leu.2011.131 Cavo, 2010, Lancet, 376, 2075, 10.1016/S0140-6736(10)61424-9 Chanan-Khan, 2010, Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response, Cancer, 117, 2127, 10.1002/cncr.25748 Chanan-Khan, 2006, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study, J Clin Oncol, 24, 5343, 10.1200/JCO.2005.05.0401 Chanan-Khan, 2005, Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL), Blood, 106, 3348, 10.1182/blood-2005-02-0669 Chanan-Khan, 2008, Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia, J Clin Oncol, 26, 4851, 10.1200/JCO.2008.18.2857 Chen, 2011, Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia, J Clin Oncol, 29, 1175, 10.1200/JCO.2010.29.8133 Czuczman, 2011, The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin, Br J Haematol, 154, 477, 10.1111/j.1365-2141.2011.08781.x Damaj, 2003, Thalidomide therapy induces response in relapsed mantle cell lymphoma, Leukemia, 17, 1914, 10.1038/sj.leu.2403058 D'Amato, 1994, Thalidomide is an inhibitor of angiogenesis, Proc Natl Acad Sci U S A, 91, 4082, 10.1073/pnas.91.9.4082 Di Raimondo, 2000, Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood, Haematologica, 85, 800 Dimopoulos, 2010, The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function, Cancer, 116, 3807, 10.1002/cncr.25139 Dimopoulos, 2007, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma, N Engl J Med, 357, 2123, 10.1056/NEJMoa070594 Dogan, 2005, Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide, Leukemia, 19, 873, 10.1038/sj.leu.2403710 Eisen, 2010, Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma, Cancer, 116, 146 Facon, 2007, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial, Lancet, 370, 1209, 10.1016/S0140-6736(07)61537-2 Fehniger, 2011, A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma, Blood, 118, 5119, 10.1182/blood-2011-07-362475 Fehniger, 2011, A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. [Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't], Blood, 117, 1828, 10.1182/blood-2010-07-297143 Fenaux, 2011, A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q, Blood, 118, 3765, 10.1182/blood-2011-01-330126 Ferrajoli, 2008, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia, Blood, 111, 5291, 10.1182/blood-2007-12-130120 Gay, 2010, Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma, Am J Hematol, 85, 664, 10.1002/ajh.21777 Ghosh, 2011, Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma, Br J Haematol, 152, 593, 10.1111/j.1365-2141.2010.08534.x Giannopoulos, 2009, Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia, Leukemia, 23, 1771, 10.1038/leu.2009.98 Glaspy, 2009, Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma, Cancer, 115, 5228, 10.1002/cncr.24576 Hofmeister, 2011, Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein, J Clin Oncol, 29, 3427, 10.1200/JCO.2010.32.4962 Hulin, 2009, Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial, J Clin Oncol, 27, 3664, 10.1200/JCO.2008.21.0948 Infante, 2011, A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer, Eur J Cancer, 47, 199, 10.1016/j.ejca.2010.09.002 Ito, 2011, Teratogenic effects of thalidomide: molecular mechanisms, Cell Mol Life Sci, 68, 1569, 10.1007/s00018-010-0619-9 Ito, 2010, Identification of a primary target of thalidomide teratogenicity, Science, 327, 1345, 10.1126/science.1177319 Jabbour, 2011, Comparison of thalidomide and lenalidomide as therapy for myelofibrosis, Blood, 118, 899, 10.1182/blood-2010-12-325589 Jakubowiak, 2011, Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial, Blood, 118, 535, 10.1182/blood-2011-02-334755 Kapoor, 2011, Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis, Leukemia, 25, 689, 10.1038/leu.2010.313 Kaufmann, 2004, Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma, Blood, 104, 2269, 10.1182/blood-2004-03-1091 Kneppers, 2011, Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial, Blood, 118, 2413, 10.1182/blood-2011-04-348292 Knop, 2009, Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom), Blood, 113, 4137, 10.1182/blood-2008-10-184135 Koh, 2005, Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis, Blood, 105, 3833, 10.1182/blood-2004-03-0828 Kropff, 2011, Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial, Haematologica, 97, 784, 10.3324/haematol.2011.044271 Kumar, 2007, Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma, Leukemia, 21, 2035, 10.1038/sj.leu.2404801 Kumar, 2010, Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study, Leukemia, 24, 1350, 10.1038/leu.2010.116 Kumar, 2011, Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial, Am J Hematol, 86, 640, 10.1002/ajh.22053 Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 Kurtin, 2009, Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. [Case Reports Research Support, Non-U.S. Gov't], Clin Lymphoma Myeloma, 9, E10, 10.3816/CLM.2009.n.053 Lacy, 2011, Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease, Blood, 118, 2970, 10.1182/blood-2011-04-348896 Lacy, 2009, Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma, J Clin Oncol, 27, 5008, 10.1200/JCO.2009.23.6802 Lacy, 2010, Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM), Leukemia, 24, 1934, 10.1038/leu.2010.190 Lacy, 2011, Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years Landgren, 2011, Myeloma and second primary cancers, N Engl J Med, 365, 2241, 10.1056/NEJMc1111010 Lapalombella, 2008, Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells, Blood, 112, 5180, 10.1182/blood-2008-01-133108 Larocca, 2012, Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide, Blood, 119, 933, 10.1182/blood-2011-03-344333 Lee, 2006, Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 898, 10.1200/JCO.2005.03.7309 Lee, 2009, Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 27, 5248, 10.1200/JCO.2009.21.9733 Leleu, 2011, High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009–02 Lentzsch, 2012, Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study, Blood, 119, 4608, 10.1182/blood-2011-12-395715 Leone, 2011, Therapy-related myeloid neoplasms, Curr Opin Oncol, 23, 672, 10.1097/CCO.0b013e32834bcc2a Li, 2011, IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM, Blood, 117, 5157, 10.1182/blood-2010-10-314278 List, 2006, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, N Engl J Med, 355, 1456, 10.1056/NEJMoa061292 List, 2005, Efficacy of lenalidomide in myelodysplastic syndromes. [Clinical Trial Research Support, U.S. Gov't, P.H.S.], N Engl J Med, 352, 549, 10.1056/NEJMoa041668 Liu, 2011, IMiD® Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit the Maturation of Megakaryocytes by Suppressing the Expression of GATA1 Lokhorst, 2010, A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma, Blood, 115, 1113, 10.1182/blood-2009-05-222539 Lopez-Girona, 2011, Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response, Br J Haematol, 154, 325, 10.1111/j.1365-2141.2011.08689.x Lopez-Girona, 2012, Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide, Leukemia, 10.1038/leu.2012.119 Ludwig, 2010, Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma, Haematologica, 95, 1548, 10.3324/haematol.2009.020586 Ludwig, 2009, Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma, Blood, 113, 3435, 10.1182/blood-2008-07-169565 Mailankody, 2011, Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS), Blood, 118, 4086, 10.1182/blood-2011-05-355743 Mark, 2008, Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma, Biol Blood Marrow Transplant, 14, 795, 10.1016/j.bbmt.2008.04.008 Mateos, 2010, J Clin Oncol, 28, 2259, 10.1200/JCO.2009.26.0638 Mazumder, 2008, Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients, Leukemia, 22, 1280, 10.1038/sj.leu.2405035 McCarthy, 2012, Lenalidomide after stem-cell transplantation for multiple myeloma, N Engl J Med, 366, 1770, 10.1056/NEJMoa1114083 Mesa, 2010, Phase1/-2 study of Pomalidomide in myelofibrosis, Am J Hematol, 85, 129 Mesa, 2010, Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903, Blood, 116, 4436, 10.1182/blood-2010-05-287417 Micallef, 2011, Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide, Bone Marrow Transplant, 46, 350, 10.1038/bmt.2010.118 Mollgard, 2011, Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities, Haematologica, 96, 963, 10.3324/haematol.2010.039669 Morabito, 2011, Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment, Blood, 118, 5759, 10.1182/blood-2011-05-353995 Moreau, 2011, Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma, Blood, 118, 5752, 10.1182/blood-2011-05-355081 Morgan, 2011, Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation, Blood, 118, 1231, 10.1182/blood-2011-02-338665 Morgan, 2012, The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis, Blood, 119, 7, 10.1182/blood-2011-06-357038 Moutouh-de Parseval, 2008, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells, J Clin Invest, 118, 248, 10.1172/JCI32322 Moutouh-de Parseval, 2007, Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia, J Clin Oncol, 25, 5047, 10.1200/JCO.2007.14.2141 Muntean, 2007, Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization, Blood, 109, 5199, 10.1182/blood-2006-11-059378 Nair, 2010, Superior results of Total Therapy 3 (2003–33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006–66 with VRD maintenance, Blood, 115, 4168, 10.1182/blood-2009-11-255620 Nowakowski, 2011, Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study, Leukemia, 25, 1877, 10.1038/leu.2011.165 Oliva, 2010, Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't], Eur J Haematol, 85, 231, 10.1111/j.1600-0609.2010.01473.x Ormerod, 2011, Observations of Second Primary Malignancy in Patients With Multiple Myeloma, Clin Lymphoma Myeloma Leuk, 12, 113, 10.1016/j.clml.2011.11.003 Pal, 2010, Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia, Blood, 115, 605, 10.1182/blood-2009-05-221077 Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial, Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4 Palumbo, 2008, Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial, Blood, 112, 3107, 10.1182/blood-2008-04-149427 Palumbo, 2010, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial, J Clin Oncol, 28, 5101, 10.1200/JCO.2010.29.8216 Palumbo, 2007, Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network, J Clin Oncol, 25, 4459, 10.1200/JCO.2007.12.3463 Palumbo, 2010, Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients, J Clin Oncol, 28, 800, 10.1200/JCO.2009.22.7561 Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 Palumbo, 2010, Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma, Leukemia, 24, 1037, 10.1038/leu.2010.58 Palumbo, 2008, Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma, Leukemia, 22, 414, 10.1038/sj.leu.2405062 Pellagatti, 2007, Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients, Proc Natl Acad Sci U S A, 104, 11406, 10.1073/pnas.0610477104 Pujol, 2007, Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00–01, J Clin Oncol, 25, 3945, 10.1200/JCO.2007.11.8109 Quintas-Cardama, 2009, Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis, J Clin Oncol, 27, 4760, 10.1200/JCO.2009.22.6548 Rajkumar, 2006, Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group, J Clin Oncol, 24, 431, 10.1200/JCO.2005.03.0221 Rajkumar, 1999, Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma, Leukemia, 13, 469, 10.1038/sj.leu.2401336 Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial, Lancet Oncol, 11, 29, 10.1016/S1470-2045(09)70284-0 Rajkumar, 2008, Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma, J Clin Oncol, 26, 2171, 10.1200/JCO.2007.14.1853 Ramasamy, 2006, Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone, Haematologica, 91, ECR44 Raza, 2001, Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes, Blood, 98, 958, 10.1182/blood.V98.4.958 Raza, 2008, Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q, Blood, 111, 86, 10.1182/blood-2007-01-068833 Richardson, 2009, Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma, Blood, 114, 772, 10.1182/blood-2008-12-196238 Richardson, 2011 Richardson, 2009, Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma, J Clin Oncol, 27, 5713, 10.1200/JCO.2009.22.2679 Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma, Blood, 116, 679, 10.1182/blood-2010-02-268862 Rubenstein, 2011, Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy, J Clin Oncol, 29, e595, 10.1200/JCO.2011.34.7252 San Miguel, 2008, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't], N Engl J Med, 359, 906, 10.1056/NEJMoa0801479 San-Miguel, 2011, Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone, Clin Lymphoma Myeloma Leuk, 11, 38, 10.3816/CLML.2010.n.120 Schey, 2004, Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma, J Clin Oncol, 22, 3269, 10.1200/JCO.2004.10.052 Schey, 2010, The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study, Br J Haematol, 150, 326, 10.1111/j.1365-2141.2010.08250.x Sekeres, 2011, A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. [Clinical Trial, Phase II Research Support, N.I.H., Extramural], Blood, 118, 523, 10.1182/blood-2011-02-337303 Sekeres, 2010, Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. [Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural], J Clin Oncol, 28, 2253, 10.1200/JCO.2009.26.0745 Sekeres, 2008, Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. [Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't], J Clin Oncol, 26, 5943, 10.1200/JCO.2007.15.5770 Sekeres, 2011, Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. [Case Reports Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural], Am J Hematol, 86, 102, 10.1002/ajh.21891 Sher, 2010, Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics, Leuk Lymphoma, 51, 85, 10.3109/10428190903406806 Sheskin, 1965, Thalidomide in the Treatment of Lepra Reactions, Clin Pharmacol Ther, 6, 303, 10.1002/cpt196563303 Short, 2011, Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma, Leukemia, 25, 906, 10.1038/leu.2011.29 Sibon, 2012, Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents, Br J Haematol, 156, 619, 10.1111/j.1365-2141.2011.08979.x Spencer, 2009, Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure, J Clin Oncol, 27, 1788, 10.1200/JCO.2008.18.8573 Stadtmauer, 2009, Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma, Eur J Haematol, 82, 426, 10.1111/j.1600-0609.2009.01257.x Streetly, 2008, Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation, Br J Haematol, 141, 41, 10.1111/j.1365-2141.2008.07013.x Tefferi, 2006, Lenalidomide therapy in myelofibrosis with myeloid metaplasia, Blood, 108, 1158, 10.1182/blood-2006-02-004572 Tefferi, 2007, Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions, Leukemia, 21, 1827, 10.1038/sj.leu.2404711 Tefferi, 2009, Pomalidomide is active in the treatment of anemia associated with myelofibrosis, J Clin Oncol, 27, 4563, 10.1200/JCO.2008.21.7356 Tehranchi, 2010, Persistent malignant stem cells in del(5q) myelodysplasia in remission. [Research Support, Non-U.S. Gov't], N Engl J Med, 363, 1025, 10.1056/NEJMoa0912228 Tueger, 2006, Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT, Haematologica, 91, ECR16 Verhelle, 2007, Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells, Cancer Res, 67, 746, 10.1158/0008-5472.CAN-06-2317 Waage, 2010, Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma, Blood, 116, 1405, 10.1182/blood-2009-08-237974 Weber, 2007, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America, N Engl J Med, 357, 2133, 10.1056/NEJMoa070596 Wiernik, 2008, Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma, J Clin Oncol, 26, 4952, 10.1200/JCO.2007.15.3429 Wijermans, 2010, Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study, J Clin Oncol, 28, 3160, 10.1200/JCO.2009.26.1610 Witzig, 2011, An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, Ann Oncol, 22, 1622, 10.1093/annonc/mdq626 Witzig, 2009, Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma, J Clin Oncol, 27, 5404, 10.1200/JCO.2008.21.1169 Ximeri, 2010, Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion, Haematologica, 95, 406, 10.3324/haematol.2009.010876 Zaja, 2012, Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers, Haematologica, 97, 416, 10.3324/haematol.2011.051813 Zhu, 2011, Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide, Blood, 118, 4771, 10.1182/blood-2011-05-356063